Quidel Corp (QDEL) Tops Q4 EPS by 20c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Needham Starts NeoVolta (NEOV) at Buy
Quidel Reports Fourth Quarter and Full Year 2018 Financial Results
February 13, 2019 4:10 PM ESTSAN DIEGO--(BUSINESS WIRE)-- Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today financial results for the fourth quarter and year ended December31, 2018.
Fourth Quarter 2018 Highlights:
Total revenue grew 15% to $132.6 million as compared to $114.9 million in the fourth quarter of 2017. Quidels legacy revenue grew 3% from the fourth quarter of 2017 to $69.6 million. Total influenza revenue increased 4% from the fourth quarter of 2017 to $34.9 million. Cardiac Immunoassay revenue grew 34% from the fourth... More